Grupo de Engenharia Metabólica Aplicada a Bioprocessos, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília SGAN, Quadra 916, Módulo B, Av. W5 Norte, CEP 70.790-160 Brasília-DF, Brazil.
Curr Protein Pept Sci. 2013 Nov;14(7):556-67. doi: 10.2174/13892037113149990071.
Numerous peptides are available on the market as therapeutic drugs for regulating tumor growth, microorganism proliferation, immune response and/or metabolic disorders. Peptides are produced either by chemical synthesis or heterologous expression. Independent of the method chosen, there are challenges to transferring its production from the bench (mg/L) to the industrial (g/L) scale. Thus, the main scale-up pitfalls for the two methods of peptide production are reviewed here, including the advantages of each. Moreover, there will be a special focus on the main challenges for large-scale, heterologous production systems. Peptides that are currently available on the market are also described with an emphasis on how their process optimization has been designed in order to develop a cost-effective product.
市场上有许多肽类药物可用于调节肿瘤生长、微生物增殖、免疫反应和/或代谢紊乱。这些肽可以通过化学合成或异源表达来生产。无论选择哪种方法，都存在将其生产从实验室规模（mg/L）转移到工业规模（g/L）的挑战。因此，本文综述了这两种肽生产方法的主要放大陷阱，包括每种方法的优点。此外，还将特别关注大规模异源生产系统的主要挑战。本文还描述了目前市场上可用的肽类药物，并重点介绍了为开发具有成本效益的产品而对其工艺进行优化的设计。
